The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

Percheron Therapeutics completes cancer treatment drug substance manufacture milestone

Percheron Therapeutics has achieved a major milestone in the commercial development of its lead candidate HMBD-002.
Felix, an automated sperm separation device used in IVF, is grabbing growing international attention.

Memphasys lands national Monash IVF supply deal for Felix system

Memphasys has secured a 12-month exclusive national supply agreement with Monash IVF for its Felix sperm…

Paradigm clears key Phase 3 hurdle as osteoarthritis trial enrolment completes

Paradigm Biopharmaceuticals has completed enrolment in its pivotal Phase 3 osteoarthritis trial, with top-line results due…

Echo IQ teams up with Mayo Clinic to evaluate AI cardiac risk tool in cancer patients

Echo IQ has secured a research collaboration with Mayo Clinic to evaluate its AI-powered cardiac risk…